📊 MCRB Key Takeaways
Is Seres Therapeutics, Inc. (MCRB) a Good Investment?
Seres Therapeutics is a pre-revenue stage biopharmaceutical company with severe financial distress characterized by massive operating losses ($94M) against minimal revenue ($789K), indicating the core business is not generating economic value. The company faces acute solvency risks with long-term debt of $110M exceeding total assets of $138M, while operating cash flow of $1.1M is insufficient to service debt obligations, suggesting potential covenant violations or refinancing requirements.
Why Buy Seres Therapeutics, Inc. Stock? MCRB Key Strengths
- Positive net income of $5.7M driven by non-operating gains, indicating potential one-time favorable items or investment income
- Adequate liquidity with $45.8M cash and 2.56x current ratio providing near-term operational runway
- Positive free cash flow of $865K suggests modest operational efficiency despite massive operating losses
MCRB Stock Risks: Seres Therapeutics, Inc. Investment Risks
- Unsustainable operating model with -11,910% operating margin and $94M operating losses against $789K revenue indicates business model fundamentally broken
- Critical debt-to-equity ratio of 2.49x with $110M long-term debt exceeding total assets of $138M creates insolvency risk
- Operating cash flow of $1.1M is inadequate to service $110M debt burden, making refinancing or restructuring likely inevitable
- Quick ratio of -0.19x indicates inability to meet short-term obligations with liquid assets, signaling imminent liquidity crisis
Key Metrics to Watch
- Revenue growth and path to commercial viability of primary pipeline assets
- Operating cash burn rate and months of cash runway remaining
- Debt maturity schedule and refinancing capacity in capital markets
Seres Therapeutics, Inc. (MCRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 109.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.56x current ratio provides a solid financial cushion.
MCRB Profit Margin, ROE & Profitability Analysis
MCRB vs Healthcare Sector: How Seres Therapeutics, Inc. Compares
How Seres Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Seres Therapeutics, Inc. Stock Overvalued? MCRB Valuation Analysis 2026
Based on fundamental analysis, Seres Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Seres Therapeutics, Inc. Balance Sheet: MCRB Debt, Cash & Liquidity
MCRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Seres Therapeutics, Inc.'s revenue has grown significantly by 348% over the 5-year period, indicating strong business expansion. The most recent EPS of $-17.77 indicates the company is currently unprofitable.
MCRB Revenue Growth, EPS Growth & YoY Performance
MCRB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $351.0K | $8.2M | $0.94 |
| Q3 2022 | $3.4M | -$15.6M | $-0.17 |
| Q2 2022 | $1.2M | -$35.5M | $-0.53 |
| Q1 2022 | $1.5M | -$35.5M | N/A |
| Q3 2021 | $80.0K | -$15.6M | $-0.17 |
| Q2 2021 | $5.2M | -$19.9M | N/A |
| Q1 2021 | $4.6M | -$19.9M | N/A |
| Q3 2020 | $80.0K | -$10.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Seres Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MCRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Seres Therapeutics, Inc. (CIK: 0001609809)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MCRB
What is the AI rating for MCRB?
Seres Therapeutics, Inc. (MCRB) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MCRB's key strengths?
Claude: Positive net income of $5.7M driven by non-operating gains, indicating potential one-time favorable items or investment income. Adequate liquidity with $45.8M cash and 2.56x current ratio providing near-term operational runway.
What are the risks of investing in MCRB?
Claude: Unsustainable operating model with -11,910% operating margin and $94M operating losses against $789K revenue indicates business model fundamentally broken. Critical debt-to-equity ratio of 2.49x with $110M long-term debt exceeding total assets of $138M creates insolvency risk.
What is MCRB's revenue and growth?
Seres Therapeutics, Inc. reported revenue of $789.0K.
Does MCRB pay dividends?
Seres Therapeutics, Inc. does not currently pay dividends.
Where can I find MCRB SEC filings?
Official SEC filings for Seres Therapeutics, Inc. (CIK: 0001609809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MCRB's EPS?
Seres Therapeutics, Inc. has a diluted EPS of $0.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MCRB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Seres Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MCRB stock overvalued or undervalued?
Valuation metrics for MCRB: ROE of 12.9% (sector avg: 15%), net margin of 721.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MCRB stock in 2026?
Our dual AI analysis gives Seres Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is MCRB's free cash flow?
Seres Therapeutics, Inc.'s operating cash flow is $1.1M, with capital expenditures of $252.0K. FCF margin is 109.6%.
How does MCRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 721.9% (avg: 12%), ROE 12.9% (avg: 15%), current ratio 2.56 (avg: 2).
Is Seres Therapeutics, Inc. carrying too much debt?
MCRB has a debt-to-equity ratio of 2.49x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.56 suggests adequate short-term liquidity.